The following companies belonging to the healthcare sector reported quarterly financial results and provided pipeline updates. <\/p>\n
1. The Cooper Companies Inc. (COO)<\/B>, which reported strong revenue growth for its fiscal second quarter ended April 30, 2022, is continuing to see strong momentum.<\/p>\n
Revenue was $829.8 million for the second quarter of 2022 compared to $719.5 million in the year-earlier quarter, an increase of 15%.<\/p>\n
On a GAAP basis, net income increased to $126.6 million or $2.55 per share from $117.5 million or $2.36 per share in the year-ago period. On a non-GAAP basis, earnings per share declined to $3.24 in Q2, 2022 from $3.38 in Q2, 2021.<\/p>\n
Looking ahead to fiscal year 2022, the company expects non-GAAP EPS in the range of $13.09 to $13.29 on revenue range of $3,280 million to $3,312 million. Earlier, the company had forecast non-GAAP EPS outlook in the range of $13.70 to $14.20 and revenue range of $3,261 million to $3,329 million.<\/p>\n
Non-GAAP EPS was $13.24 and revenue was $2,922.5 million in fiscal year 2021.<\/p>\n
COO closed Thursday’s trading at $352.81, up 2.80%.<\/p>\n
2. Genetron Holdings Limited (GTH)<\/B>, which reported nearly 20% revenue growth in its first quarter ended March 31, 2022, is confident about its long-term competitive position.<\/p>\n
The company specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development.<\/p>\n
The loss per ordinary share attributable to owners of the company widened to RMB 0.38 (US $0.06) for the first quarter of 2022 from RMB 0.25 for the same period of 2021. Revenue for the first quarter of 2022 increased by 19.8% to RMB 110.3 million (US $17.4 million) from RMB 92.1 million in the year-ago period.<\/p>\n
Looking ahead to full-year 2022, the company continues to expect revenue to be around RMB 585-638 million, representing 10-20% growth over its revenue in 2021. Revenue was RMB532.0 million (US$83.5 million) in 2021.<\/p>\n
GTH closed Thursday’s trading at $1.52, up 2.70%.<\/p>\n
3. Immatics N.V. (IMTX)<\/B>, a clinical-stage biopharmaceutical company, provided a pipeline update on Thursday.<\/p>\n
The company’s pipeline includes IMA401, IMA402, and IMA40X.<\/p>\n
— IMA401 advanced into a phase I trial in patients with recurrent and\/or refractory solid tumors last month. This compound is being developed in collaboration with Bristol Myers Squibb.
— IMA402 is expected to advance into a phase I trial in 2023. IMA402 is directed against a peptide derived from the cancer target PRAME, a protein that is frequently expressed in many solid cancers.
— IMA40X, for an undisclosed indication, is under preclinical testing.<\/p>\n
IMTX closed Thursday’s trading at $7.79, up 3.18%.<\/p>\n
4. NuCana plc (NCNA)<\/B> has multiple data readouts lined up for this year. <\/p>\n
The company’s pipeline includes NUC-3373 and NUC-7738.<\/p>\n
NUC-3373 is in a phase 1b\/2 studies in patients with metastatic colorectal cancer. NUC-7738 is in a phase 1\/2 study for patients with advanced solid tumors.<\/p>\n
NUC-3373:<\/p>\n
— Data from the Phase 1b\/2 study of NUC-3373 combined with leucovorin, irinotecan and bevacizumab in patients with colorectal cancer is expected to be announced this year.
— Data from the Phase 1b\/2 modular study of NUC-3373 in combination with other agents in patients with solid tumors to identify additional indications for development are also expected this year. <\/p>\n
NUC-7738:<\/p>\n
— Data from the phase 1 part and phase 2 part of the phase 1\/2 study of NUC-7738 in patients with advanced solid tumors is expected this year.<\/p>\n
As of March 31, 2022, the company had cash and cash equivalents of \u00a352.6 million.<\/p>\n
NCNA closed Thursday’s trading at $0.60, up 3.66%.<\/p>\n
5. Phreesia Inc. (PHR)<\/B>, which provides healthcare organizations a suite of robust applications to manage the patient intake process, has reported strong financial results for the fiscal first quarter ended April 30, 2022.<\/p>\n
Net loss for the fiscal first quarter of 2023 widened to $51.2 million or $0.99 per share from $10.97 million or $0.24 per share in the year-ago period. Total revenue for the quarter jumped to $63.35 million from $48.29 million in the year-earlier quarter.<\/p>\n
Average number of healthcare services clients increased 33% to 2,526 in fiscal Q1, 2023 from 1,902 in the same period in the prior year.<\/p>\n
For fiscal 2023, the company expects revenue in the range of $271 million to $275 million implying year-over-year growth of 27% to 29%.<\/p>\n
PHR closed Thursday’s trading at $19.00, up 4.63%.<\/p>\n
6. Procaps Group S.A. (PROC)<\/B>, a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies, has turned around to profit for the quarter ended March 31, 2022.<\/p>\n
According to preliminary financial results reported yesterday, net income for the first quarter of 2022 was $16.4 million on revenue of $85.6 million. This compared with a net loss of $17.0 million and revenue of $77.4 million in the year-ago quarter.<\/p>\n
The net income for Q1, 2022 included a U$20.2 million non-cash gain from the re-valuation of the company’s ordinary shares held in escrow and warrant liabilities.<\/p>\n
The company expects to report its complete first quarter 2022 financial results in the next few weeks.<\/p>\n
PROC closed Thursday’s trading at $9.05, up 6.47%. <\/p>\n